Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Metzelder

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Deutsche Medizinische Wochenschrift (1946)|August 27, 2010
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]S K Metzelder, E Wollmer, A Neubauer, et al.
Ultrasound International Open|October 1, 2016
71-Year-Old Patient with Chronic Lymphocytic Leukemia (CLL) and Hypoechoic Nodular Spleen and Liver Lesions with Fatal Outcome: Presentation of Mucormycosis in B-Mode Imaging and Contrast-Enhanced Ultrasound (CEUS)C Trenker, M Dohse, S K Metzelder, et al.
Der Internist|June 30, 2009
["Malignant" ARDS]S K Metzelder, C Reinke, E M Walthers, et al.
Leukemia|July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)G Bug, A Burchert, E-M Wagner, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Leukemia|February 20, 2004
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemiaC Müller-Tidow, S K Metzelder, H Buerger, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|August 27, 2010
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option]S K Metzelder, E Wollmer, A Neubauer, et al.
Ultrasound International Open|October 1, 2016
71-Year-Old Patient with Chronic Lymphocytic Leukemia (CLL) and Hypoechoic Nodular Spleen and Liver Lesions with Fatal Outcome: Presentation of Mucormycosis in B-Mode Imaging and Contrast-Enhanced Ultrasound (CEUS)C Trenker, M Dohse, S K Metzelder, et al.
Der Internist|June 30, 2009
["Malignant" ARDS]S K Metzelder, C Reinke, E M Walthers, et al.
Leukemia|July 29, 2017
Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)G Bug, A Burchert, E-M Wagner, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Leukemia|February 20, 2004
Expression of the p14ARF tumor suppressor predicts survival in acute myeloid leukemiaC Müller-Tidow, S K Metzelder, H Buerger, et al.
Leukemia|May 16, 2015
NFATc1 as a therapeutic target in FLT3-ITD-positive AMLS K Metzelder, C Michel, M von Bonin, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2017
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantationS K Metzelder, T Schroeder, M Lübbert, et al.
Leukemia|April 17, 2012
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responsesS K Metzelder, T Schroeder, A Finck, et al.
Leukemia|January 12, 2017
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CMLC Schütz, S Inselmann, S Saussele, et al.
Pageof 2